Aemetis (NASDAQ:AMTX) Shares Pass Below Two Hundred Day Moving Average - Time to Sell?

Key Points

• Aemetis shares fell below their 200-day moving average, trading as low as $1.74 versus the $2.10 average, and last changed hands at $1.83.
• Analyst sentiment is mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus Hold rating and an $11.88 average price target.
• Aemetis reported a quarterly loss of $0.13 per share, better than the expected $0.29 loss, but revenue of $62.7 million came in below the $67.69 million estimate; analysts expect a full-year loss of $0.89 per share.

Shares of Aemetis, Inc (NASDAQ:AMTX - Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.10 and traded as low as $1.74. Aemetis shares last traded at $1.83, with a volume of 711,376 shares traded.

Analyst Upgrades and Downgrades

A number of brokerages have commented on AMTX. Weiss Ratings restated a "sell (e+)" rating on shares of Aemetis in a research note on Friday, July 17th. Wall Street Zen upgraded shares of Aemetis from a "sell" rating to a "hold" rating in a research report on Saturday, August 22nd. Finally, Ascendiant Capital Markets increased their target price on Aemetis from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, May 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $11.88.

Aemetis Stock Up 4.0%

The stock has a market capitalization of $132.07 million, a price-to-earnings ratio of -2.01 and a beta of 1.47. The company's fifty day simple moving average is $1.72 and its 200 day simple moving average is $2.10.

Aemetis (NASDAQ:AMTX - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The specialty chemicals company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.16. The business had revenue of $62.70 million during the quarter, compared to analyst estimates of $67.69 million. As a group, analysts anticipate that Aemetis, Inc will post -0.89 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AMTX. Bank of America Corp DE boosted its holdings in Aemetis by 148.3% during the first quarter. Bank of America Corp DE now owns 101,486 shares of the specialty chemicals company's stock worth $324,000 after purchasing an additional 60,611 shares during the last quarter. Royal Bank of Canada lifted its position in shares of Aemetis by 10,632.5% during the 1st quarter. Royal Bank of Canada now owns 8,908 shares of the specialty chemicals company's stock worth $28,000 after buying an additional 8,825 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Aemetis in the 4th quarter worth approximately $31,000. HRT Financial LP purchased a new position in Aemetis in the fourth quarter worth $36,000. Finally, Centiva Capital LP bought a new position in Aemetis during the third quarter valued at about $39,000. Institutional investors own 27.02% of the company's stock.

About Aemetis

Aemetis, Inc, headquartered in Cupertino, California, is a renewable fuels and renewable natural gas producer dedicated to decarbonizing the transportation sector. The company operates two primary business segments: Aemetis Advanced Fuels, which manufactures ethanol, biodiesel and sustainable aviation fuel using patented carbon capture and separation technology; and Aemetis RNG, which develops dairy-based renewable natural gas projects in California for pipeline injection and transportation use.

Since its incorporation in 2006, Aemetis has expanded its production footprint through organic growth and strategic acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.